TY  - JOUR
AU  - Bondžić, Bojan
AU  - Džambaski, Zdravko
AU  - Kolarević, Ana
AU  - Đorđević, Aleksandra
AU  - Anderluh, Marko
AU  - Šmelcerović, Andrija
PY  - 2019
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/3957
AB  - Eight new benzocyclobutane-2,5-diones (1a–1h) were synthesized, and their inhibitory properties
against bovine pancreatic DNase I were examined in vitro. Methods & results: Compounds 1a–1h
were synthesized using photocycloaddition of duroquinone with various phenyl-substituted ethylenes
in the presence of 18W compact fluorescent lamp (visible light). Two compounds, 1,3,4,6-tetramethyl-7-
phenylbicyclo[4.2.0]oct-3-ene-2,5-dione (1a) and 1,3,4,6-tetramethyl-7-p-tolylbicyclo[4.2.0]oct-3-ene-2,5-
dione (1b) inhibited DNase I in a noncompetitive manner with IC50 values below 150 μM and showed to
be more potent DNase I inhibitors than crystal violet, used as a positive control. In order to analyze potential
binding sites for the studied compounds with DNase I, molecular docking study was performed.
Conclusion: The studied benzocyclobutane-2,5-diones offer a good starting point for a design of new
DNase I inhibitors.
PB  - Future Medicine Ltd.
T2  - Future Medicinal Chemistry
T1  - Synthesis and DNase I inhibitory properties of new benzocyclobutane-2,5-diones
VL  - 11
VL  - 2426
IS  - 18
SP  - 2415
DO  - 10.4155/fmc-2019-0032
ER  - 

@article{
author = "Bondžić, Bojan and Džambaski, Zdravko and Kolarević, Ana and Đorđević, Aleksandra and Anderluh, Marko and Šmelcerović, Andrija",
year = "2019",
abstract = "Eight new benzocyclobutane-2,5-diones (1a–1h) were synthesized, and their inhibitory properties
against bovine pancreatic DNase I were examined in vitro. Methods & results: Compounds 1a–1h
were synthesized using photocycloaddition of duroquinone with various phenyl-substituted ethylenes
in the presence of 18W compact fluorescent lamp (visible light). Two compounds, 1,3,4,6-tetramethyl-7-
phenylbicyclo[4.2.0]oct-3-ene-2,5-dione (1a) and 1,3,4,6-tetramethyl-7-p-tolylbicyclo[4.2.0]oct-3-ene-2,5-
dione (1b) inhibited DNase I in a noncompetitive manner with IC50 values below 150 μM and showed to
be more potent DNase I inhibitors than crystal violet, used as a positive control. In order to analyze potential
binding sites for the studied compounds with DNase I, molecular docking study was performed.
Conclusion: The studied benzocyclobutane-2,5-diones offer a good starting point for a design of new
DNase I inhibitors.",
publisher = "Future Medicine Ltd.",
journal = "Future Medicinal Chemistry",
title = "Synthesis and DNase I inhibitory properties of new benzocyclobutane-2,5-diones",
volume = "11, 2426",
number = "18",
pages = "2415",
doi = "10.4155/fmc-2019-0032"
}

Bondžić, B., Džambaski, Z., Kolarević, A., Đorđević, A., Anderluh, M.,& Šmelcerović, A.. (2019). Synthesis and DNase I inhibitory properties of new benzocyclobutane-2,5-diones. in Future Medicinal Chemistry
Future Medicine Ltd.., 11(18), 2415.
https://doi.org/10.4155/fmc-2019-0032

Bondžić B, Džambaski Z, Kolarević A, Đorđević A, Anderluh M, Šmelcerović A. Synthesis and DNase I inhibitory properties of new benzocyclobutane-2,5-diones. in Future Medicinal Chemistry. 2019;11(18):2415.
doi:10.4155/fmc-2019-0032 .

Bondžić, Bojan, Džambaski, Zdravko, Kolarević, Ana, Đorđević, Aleksandra, Anderluh, Marko, Šmelcerović, Andrija, "Synthesis and DNase I inhibitory properties of new benzocyclobutane-2,5-diones" in Future Medicinal Chemistry, 11, no. 18 (2019):2415,
https://doi.org/10.4155/fmc-2019-0032 . .

TY  - JOUR
AU  - Kolarević, Ana
AU  - Ilić, Budimir S.
AU  - Kocić, Gordana
AU  - Džambaski, Zdravko
AU  - Šmelcerović, Andrija
AU  - Bondžić, Bojan
PY  - 2018
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/2998
AB  - Twelve new thiazolidinones were synthesized and, together with 41 previously
synthesized thiazolidinones, evaluated for inhibitory activity against deoxyribonuclease I (DNase I) in vitro. Ten compounds inhibited commercial bovine pancreatic DNase I with an IC50 below 200 μM and showed to be more potent DNase I inhibitors than crystal violet (IC50 = 365.90 ± 47.33 μM), used as a positive control. Moreover, three compounds were active against DNase I in rat
liver homogenate, having an IC50 below 200 μM. (3‐Methyl‐1,4‐dioxothiazolidin‐2‐ylidene)‐N‐(2‐phenylethyl)ethanamide (41) exhibited the most potent DNase I inhibition against both commercial and rat liver DNase I with IC50 values of 115.96 ± 11.70 and 151.36 ± 15.85 μM, respectively. Site Finder and molecular docking defined the thiazolidinones interactions with the most important catalytic residues of DNase I, including the H‐acceptor interaction with residues His 134 and His 252 and/or H‐donor interaction with residues Glu 39 and Asp 168. The three most active compounds against both commercial and rat liver DNase I (31, 38, and 41) exhibited favorable physico‐chemical, pharmacokinetic, and toxicological properties. These observations could be
utilized to guide the rational design and optimization of novel thiazolidinone inhibitors. Thiazolidinones as novel DNase I inhibitors could have potential therapeutic applications due to the significant involvement of DNase I in the pathophysiology of many disease conditions.
PB  - Wiley
T2  - Journal of Cellular Biochemistry
T1  - Synthesis and DNase I inhibitory properties of some 4‐thiazolidinone derivatives
VL  - 120
IS  - 1
SP  - 264
EP  - 274
DO  - 10.1002/jcb.27339
ER  - 

@article{
author = "Kolarević, Ana and Ilić, Budimir S. and Kocić, Gordana and Džambaski, Zdravko and Šmelcerović, Andrija and Bondžić, Bojan",
year = "2018",
abstract = "Twelve new thiazolidinones were synthesized and, together with 41 previously
synthesized thiazolidinones, evaluated for inhibitory activity against deoxyribonuclease I (DNase I) in vitro. Ten compounds inhibited commercial bovine pancreatic DNase I with an IC50 below 200 μM and showed to be more potent DNase I inhibitors than crystal violet (IC50 = 365.90 ± 47.33 μM), used as a positive control. Moreover, three compounds were active against DNase I in rat
liver homogenate, having an IC50 below 200 μM. (3‐Methyl‐1,4‐dioxothiazolidin‐2‐ylidene)‐N‐(2‐phenylethyl)ethanamide (41) exhibited the most potent DNase I inhibition against both commercial and rat liver DNase I with IC50 values of 115.96 ± 11.70 and 151.36 ± 15.85 μM, respectively. Site Finder and molecular docking defined the thiazolidinones interactions with the most important catalytic residues of DNase I, including the H‐acceptor interaction with residues His 134 and His 252 and/or H‐donor interaction with residues Glu 39 and Asp 168. The three most active compounds against both commercial and rat liver DNase I (31, 38, and 41) exhibited favorable physico‐chemical, pharmacokinetic, and toxicological properties. These observations could be
utilized to guide the rational design and optimization of novel thiazolidinone inhibitors. Thiazolidinones as novel DNase I inhibitors could have potential therapeutic applications due to the significant involvement of DNase I in the pathophysiology of many disease conditions.",
publisher = "Wiley",
journal = "Journal of Cellular Biochemistry",
title = "Synthesis and DNase I inhibitory properties of some 4‐thiazolidinone derivatives",
volume = "120",
number = "1",
pages = "264-274",
doi = "10.1002/jcb.27339"
}

Kolarević, A., Ilić, B. S., Kocić, G., Džambaski, Z., Šmelcerović, A.,& Bondžić, B.. (2018). Synthesis and DNase I inhibitory properties of some 4‐thiazolidinone derivatives. in Journal of Cellular Biochemistry
Wiley., 120(1), 264-274.
https://doi.org/10.1002/jcb.27339

Kolarević A, Ilić BS, Kocić G, Džambaski Z, Šmelcerović A, Bondžić B. Synthesis and DNase I inhibitory properties of some 4‐thiazolidinone derivatives. in Journal of Cellular Biochemistry. 2018;120(1):264-274.
doi:10.1002/jcb.27339 .

Kolarević, Ana, Ilić, Budimir S., Kocić, Gordana, Džambaski, Zdravko, Šmelcerović, Andrija, Bondžić, Bojan, "Synthesis and DNase I inhibitory properties of some 4‐thiazolidinone derivatives" in Journal of Cellular Biochemistry, 120, no. 1 (2018):264-274,
https://doi.org/10.1002/jcb.27339 . .